FBL Avocats advised Seventure Partners and LundbeckFond Invest, existing investors in Enterome, on the French biotech company’s eighth financing round, raising €16.5 million (US$19 million).
FBL Avocats advised Seventure Partners and LundbeckFond Invest, existing investors in the French biotechnology company specialising in immuno-oncology. The company has already completed phase 1/2 clinical trials for two of its flagship candidates (EO4010 and EO2401) and is now launching a new phase 1/2 trial for EO2463, targeting indolent non-Hodgkin lymphomas.
The €16.5 million (US$19 million) round, led by the US-based Institute for Follicular Lymphoma Innovation (IFLI) and supported by existing investors Seventure Partners, LundbeckFond Invest, Primo Capital, SymBiosis and The Leukemia & Lymphoma Society, brings the company’s total equity funding since inception to more than US$140 million, in addition to US$100 million in non-dilutive funding. It will enable Enterome to continue developing its portfolio of innovative OncoMimics™ immunotherapies.
Having supported Seventure Partners on several landmark life sciences transactions, FBL Avocats further strengthens its role as an adviser to investors in the dynamic and innovative biotech sector.
Advisers:
Legal advisers to Seventure Partners and LundbeckFund Invest: FBL Avocats (Misha Raznatovich and Laura Simentic)
Legal advisers to Enterome: Bird&Bird (Emmanuelle Porte, Sylvie Hamel, Hugo Vallespi)
Legal advisers to Symbiosis: Taylor Wessing (Amira Abaoub and Sandra Baes)
About Seventure Partners – https://www.seventure.fr/
As an active partner to innovative companies with strong growth potential, Seventure has invested in the most innovative sectors since 1997. With more than €1 billion under management, Seventure is one of Europe’s leading venture capital firms. It invests in life sciences throughout Europe, North America, Asia and Israel, in information and communication technologies in France and Germany, and in the sports economy. Its main life sciences investment areas are industrial biotechnology, health and nutrition, and the microbiome.
About Enterome – https://www.enterome.com/
Enterome is a French clinical-stage biotechnology company developing innovative OncoMimics™ immunotherapies for cancer treatment: a proprietary new class of immunotherapies inspired by the microbial origin of certain autoimmune diseases. Its innovative platform has produced a portfolio of three clinical candidates: EO2463 for indolent non-Hodgkin lymphomas, EO4010 for third-line colorectal cancer treatment, and EO2401 for glioblastoma and adrenal tumours. Based in Paris, the company employs around a dozen people.
About FBL Avocats – https://www.fbl-avocats.com/
FBL Avocats, formerly LAMY & ASSOCIÉS, was founded in 1965 and covers the various fields of business law, in both advisory work and litigation. It brings together more than 60 lawyers in Lyon and Paris, including 22 partners. In 2016, LAMY & ASSOCIÉS joined FIDUCIAL’s legal division (1). The firm is also a member of the international TERRALEX network.
(1) A leading provider of multidisciplinary services, FIDUCIAL supports small businesses, craftspeople, retailers, independent professionals and farmers every day so they can focus on their core business. More than 325,000 clients place their trust in FIDUCIAL’s experts in law, audit and statutory audit, accounting, banking, financial advice, real estate, IT, security and office services. Driven by the entrepreneurial spirit of Christian Latouche, its founder and current Chairman, and pursuing uninterrupted growth for more than 50 years, FIDUCIAL operates in 78 countries with more than 19,000 employees generating revenue of US$1.860 billion. In Europe, FIDUCIAL has built an unrivalled territorial network of nearly 15,000 employees across 860 offices, generating revenue of €1.4 billion.

